Highest-materiality recent filing
Autolus Q1 2026: AUCATZYL net revenue $26.2M; positive gross margin; reaffirms FY revenue $120-135M
Net product revenue $26.2M (vs $9.0M Q1 2025); gross profit $1.6M, first positive quarter for ALL business.
Autolus cuts workforce 13%; expects $8M restructuring charge, $15M annualized savings
Reduces workforce ~13% as part of operational efficiency plan; impacted employees receive severance and benefits.
Autolus reports FY2025 AUCATZYL net revenue $74.3M; guides FY2026 $120-135M
Q4 2025 AUCATZYL net revenue $23.3M; full-year $74.3M, primarily from U.S. sales.
Autolus reports preliminary 2025 AUCATZYL rev $75M; guides FY2026 $120-135M
Preliminary unaudited AUCATZYL net product revenue: Q4 2025 ~$24M, full year 2025 ~$75M.
Autolus Q3 net product revenue $21.1M; RMAT for pediatric ALL; lupus data show 83% remission
Q3 2025 net product revenue of $21.1M and deferred revenue of $7.6M; net loss of $79.1M ($0.30 per share).
Autolus reports Q2 AUCATZYL revenue $20.9M; EU/UK approvals secured but Germany launch on hold
Net product revenue $20.9M in Q2, $29.9M H1 2025; 46 U.S. centers activated, >90% medical lives covered.
Autolus reports Q1 AUCATZYL revenue $9.0M; UK MHRA approval for r/r B-ALL
Q1 2025 AUCATZYL net product revenue $9.0M, first quarter of launch.
Autolus reports FY2024 net loss $220.7M; AUCATZYL launch on track with 33 U.S. centers
Net loss $220.7M ($0.86 per share) vs $208.4M ($1.20) in 2023; revenue $10.1M (up from $1.7M).
FDA approves Autolus' AUCATZYL (obe-cel) for adult r/r B-ALL; no REMS required
Approval based on FELIX trial: 63% overall complete remission (CR/CRi) in efficacy-evaluable patients (n=65); median DOR 14.1 months.
Autolus Therapeutics Q3 net loss $82M; FDA approval of AUCATZYL triggers $30M milestone
FDA approved AUCATZYL (obe-cel) for adult r/r B-ALL on Nov 8, 2024, ahead of PDUFA date.
Autolus Q2 net loss $58.3M; cash $705.9M; obe-cel PDUFA Nov 16, 2024 on track
Net loss $58.3M ($0.22/sh) vs $45.6M ($0.26/sh) in Q2 2023; cash $705.9M up from $239.6M at Dec 31, 2023.
Autolus publishes UK Annual Report; provides obe-cel BLA status, PDUFA date Nov 16, 2024
BLA for obe-cel accepted by FDA; PDUFA target action date set for 16 November 2024.
Autolus presents FELIX update: 78% ORR, 40% ongoing remission without SCT, median OS 23.8 months
ORR 78% (99/127); median EFS 11.9 months, median OS 23.8 months; 12-month OS rate 61.1%.
Autolus reports Q1 2024 net loss of $52.7M; cash $758.5M; obe-cel PDUFA Nov 16
Net loss $52.7M ($0.24 diluted EPS) vs $39.8M loss year ago; license revenue $10.1M.
John H. Johnson steps down as Chairman and Non-Executive Director; departure not due to disagreements.
Autolus restates 2021-2022 financials on R&D tax credit classification error
Error: UK SME R&D tax credits previously classified as income tax benefit should reduce R&D expense instead.
Autolus FY2023 net loss $208.4M; raises $600M via BioNTech deal and offering; CDO resigns
Net loss for FY2023 was $208.4M ($1.20 diluted EPS) vs $148.8M in 2022; cash at year-end $239.6M.
Autolus enters $200M equity deal and strategic CAR-T collaboration with BioNTech
BioNTech invests $200M in Autolus ADS at $6.00 per share, plus $50M upfront under license agreement.
Autolus prices $350M ADS offering at $6.00 per ADS for obe-cel development
Offering of 58,333,336 ADSs at $6.00/ADS for gross proceeds of $350 million.
Autolus Therapeutics announces FDA acceptance of BLA for obe-cel; PDUFA date Nov 16, 2024
FDA accepted BLA for obe-cel in relapsed/refractory Adult B-ALL; PDUFA target action date November 16, 2024.
Pooled FELIX Phase Ib/II (n=127): CR/CRi rate 78%; grade ≥3 CRS 2%, ICANS 7%; median follow-up 16.6 months.
Autolus submits BLA to FDA for cell therapy obe-cel in r/r adult B-ALL
BLA for obecabtagene autoleucel (obe-cel) submitted to FDA for relapsed/refractory adult B-cell ALL.
On May 23, 2025, Drs. Joseph Anderson and Martin Murphy, members of the Board of Directors (the “Board”) of Autolus Therapeutics plc (the “Company”), notified the Company of their intention not to stand for re-election at the Company’s 2025 Annual General Meeting of Shareholders.
On May 23, 2025, Drs. Joseph Anderson and Martin Murphy, members of the Board of Directors (the “Board”) of Autolus Therapeutics plc (the “Company”), notified the Company of their intention not to stand for re-election at the Company’s 2025 Annual General Meeting of Shareholders.
On April 3, 2025, the Board of Directors of the Company appointed Rob Dolski, the Company’s current Chief Financial Officer, to serve as the principal accounting officer of the Company in addition to his current role as principal financial officer, effective immediately.
On February 24, 2025, Andrew Mercieca notified Autolus Therapeutics plc (the “Company”) of his intention to resign from his role as the Company’s Vice President of Finance and principal accounting officer, to pursue another opportunity.
On March 26, 2024, John Johnson notified Autolus Therapeutics plc (the “Company”) of his resignation from the Board of Directors (the “Board”) of the Company, effective April 1, 2024.
appointed Michael W. (“Mike”) Bonney to serve as a Class II director of the Company and as Chair of the Board, effective April 1, 2024.
appointed Ravi M. Rao, M.D. to serve as a Class I director of the Company and member of the Research and Development Committee, effective April 1, 2024.
appointed Robert (“Bob”) W. Azelby to serve as a Class II director of the Company, effective January 9, 2024.
On December 19, 2023, Kapil Dhingra, M.D. notified Autolus Therapeutics plc (the “Company”) of his intent to resign from the Board of Directors (the “Board”) of the Company and its committees, effective December 31, 2023.
On December 22, 2023, the Company announced that the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Elisabeth (“Lis”) Leiderman, M.D. to serve as a Class II director of the Company, effective December 20, 2023.
Max materiality 0.90 · Median 0.57 · Most common event other_material